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Abstract
Following an application from DuPont Nutrition Biosciences ApS submitted for authorisation of a health
claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of
Ireland, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an
opinion on the scientific substantiation of a health claim related to Bifidobacterium animalis subsp.
lactis Bi-07 (Bi-07) and contribution to increasing lactose digestion. The scope of the application was
proposed to fall under a health claim based on newly developed scientific evidence. The food proposed
by the applicant as the subject of the health claim is Bi-07. The Panel considers that Bi-07 is
sufficiently characterised. The claimed effect proposed by the applicant is ‘improvement of lactose
digestion’. The Panel considers that increasing lactose digestion is a beneficial physiological effect for
individuals with lactose maldigestion provided that the symptoms of lactose maldigestion are improved.
Two human intervention studies which investigated a single dose effect of Bi-07 on lactose digestion
using the hydrogen breath test, as well as on gastrointestinal symptoms were submitted. These
studies show that consumption of Bi-07 (1012 CFU) increases lactose digestion in individuals with
lactose maldigestion and that Bi-07 exhibits lactase activity in vitro. However, these studies provide no
evidence that increasing lactose digestion through the consumption of Bi-07 (1012 CFU) improves
gastrointestinal symptoms of lactose maldigestion, which is considered a beneficial physiological effect.
The Panel concludes that a cause and effect relationship has not been established between the
consumption of Bifidobacterium animalis subsp. lactis Bi-07 and a beneficial physiological effect (i.e.
the improvement of symptoms of lactose maldigestion) in individuals with lactose maldigestion.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1924/2006 harmonises the provisions that relate to nutrition and health claims,
and establishes rules governing the Community authorisation of health claims made on foods. As a
rule, health claims are prohibited unless they comply with the general and specific requirements of this
Regulation, are authorised in accordance with this Regulation, and are included in the lists of
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this
Regulation lays down provisions for the addition of claims (other than those referring to the reduction
of disease risk and to children’s development and health), which are based on newly developed
scientific evidence or include a request for the protection of proprietary data, to the Community list of
permitted claims referred to in Article 13(3). According to Article 18 of this Regulation, an application
for inclusion in the Community list of permitted claims referred to in Article 13(3) shall be submitted by
the applicant to the national competent authority of a Member State, which will make the application
and any supplementary information supplied by the applicant available to the European Food Safety
Authority (EFSA).
1.2. Interpretation of the Terms of Reference
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an
opinion on the scientific substantiation of a health claim related to: Bifidobacterium animalis subsp.
lactis Bi-07 and contributes to increasing lactose digestion.
The present opinion does not constitute, and cannot be construed as, an authorisation for the
marketing of Bifidobacterium animalis subsp. lactis Bi-07, a positive assessment of its safety, nor a
decision on whether Bifidobacterium animalis subsp. lactis Bi-07 is, or is not, classified as a foodstuff.
It should be noted that such an assessment is not foreseen in the framework of Regulation (EC) No
1924/2006.
It should also be highlighted that the scope, the proposed wording of the claim and the conditions
of use as proposed by the applicant may be subject to changes, pending the outcome of the
authorisation procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006.
2. Data and methodologies
2.1. Data
Information provided by the applicant
Food/constituent as stated by the applicant
According to the applicant, the food for which the health claim is made is ‘Bifidobacterium animalis
subsp. lactis Bi-07 (Bi-07)’.
Health relationship as claimed by the applicant
According to the applicant, the health effect is related to ‘improving lactose digestion’.
Mechanism by which the food/constituent could exert the claimed effect as proposed by
the applicant
The applicant claims that: ‘(i) Bi-07 is able to digest lactose in simulated gastrointestinal
environments, similarly or better than purified laboratory grade b-galactosidase, and better than other
tested bacterial products (including standard yoghurt cultures); (ii) Bi-07 (> 1012 CFU) is able to digest
lactose similar to a target quantity of 4500 Food Chemicals Codex (FCC) of commercial lactase product
originating from Aspergillus oryzae; (iii) the freely available enzymatic activity of Bi-07 is much lower
than commercial lactase, demonstrating that Bi-07’s mechanism of effect is due to bacterial
metabolism and not by freely available enzyme’.
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Wording of the health claim as proposed by the applicant
The applicant has proposed the following wording for the health claim: ‘Bifidobacterium animalis
subsp. lactis Bi-07 contributes to the improvement of lactose digestion in individuals who have
difficulty digesting lactose’.
Specific conditions of use as proposed by the applicant
According to the applicant, the target population for the intended health claim is ‘persons with
lactose maldigestion’. The quantity of Bi-07 of at least 1012 CFU per serving is recommended.
Data provided by the applicant
The health claim application on ‘Bifidobacterium animalis subsp. lactis Bi-07 and contributes to the
improvement of lactose digestion’ pursuant to Article 13.5 of Regulation (EC) No 1924/2006, was
presented in a common and structured format as outlined in the Scientific and technical guidance for
the preparation and presentation of applications for authorisation of health claims (EFSA NDA Panel,
2016a).
As outlined in the General guidance for stakeholders on health claim applications, it is the
responsibility of the applicant to provide the totality of the available evidence.
2.2. Methodologies
The general approach of the NDA Panel for the evaluation of health claim applications is outlined in
the EFSA general guidance for stakeholders on health claim applications (EFSA NDA Panel, 2016a).
The scientific requirements for health claims related to the immune system, the gastrointestinal
tract and defence against pathogenic microorganisms are outlined in a specific EFSA guidance (EFSA
NDA Panel, 2016b).
The data claimed as proprietary are: Booster Omega Subject Classification, Booster Omega Safety
Tables, Booster Omega Certificates of Analysis for Investigational Product, Booster Omega Clinical
Study Report appendices and study reports by Forssten (2019 unpublished), Forssten and Marttinen
(2019 unpublished) and Rasinkangas (2019 unpublished).
The data claimed as confidential are: Composition of Bifidobacterium animalis subsp. lactis Bi-07,
specifications and details of test methods for Bi-07, certificates of analysis for three batches of Bi-07,
manufacturing process of Bi-07, stability data of Bi-07, certificate of analysis present in the clinical
study reports of the study by Uebelhack (2019 unpublished) and Donazzolo (2019 unpublished),
certificate of analysis of Bi-07 in the in vitro studies by Forssten (2019 unpublished), Forssten and
Marttinen (2019 unpublished) and Rasinkangas (2019 unpublished). EFSA has issued its Decision on
Confidentiality on 26/05/2020.
3. Assessment
The approach used by the NDA Panel for the evaluation of health claims is explained in the General
scientific guidance for stakeholders on health claim applications (EFSA NDA Panel, 2016a). In assessing
each specific food/health relationship, which forms the basis of a health claim the NDA Panel considers
the following key questions:
(i) the food/constituent is defined and characterised;
(ii) the claimed effect is based on the essentiality of a nutrient; OR the claimed effect is defined
and is a beneficial physiological effect for the target population and can be measured
in vivo in humans;
(iii) a cause and effect relationship is established between the consumption of the
food/constituent and the claimed effect (for the target group under the proposed conditions
of use).
Each of these three questions needs to be assessed by the NDA Panel with a favourable outcome
for a claim to be substantiated. In addition, an unfavourable outcome of the assessment of questions
(i) and/or (ii) precludes the scientific assessment of question (iii).
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3.1. Characterisation of the food/constituent
The food/constituent proposed by the applicant as the subject of the health claim is
Bifidobacterium animalis subsp. lactis Bi-07 (Bi-07).
Bi-07 is an anaerobic, Gram-positive, non-spore forming pleiotropic lactic acid bacteria (Ventura
et al., 2007; Turroni et al., 2009; Arumugam et al., 2011).
The entire genome for Bi-07 has been sequenced (Stahl and Barrangou, 2012). The genome
sequence has been deposited publicly at the National Center for Biotechnology Information (NCBI)
(NC_017867.1) and in GenBank, the National Institute of Health’s (NIH’s) genetic sequence database
(CP003498).
The strain has been deposited in the American Type Culture Collections (ATCC) safe deposit
(SD5220), and in the internal Danisco Global Culture Collection (DGCC) (DGCC 2907). The species
Bifidobacterium animalis was added to the EFSA’s Qualified Presumption of Safety (QPS) List (EFSA
BIOHAZ Panel, 2019). Bi-07 was accepted as Generally Recognised as Safe (GRAS) by the United
States Food and Drug Administration (U.S. FDA, 2013).
An overview of the manufacturing process and information regarding stability of freeze-dried
batches was provided (claimed as confidential information).
As conditions of use, the applicant indicates that the food/constituent should be consumed with
lactose containing meals in an amount of at least 1012 colony-forming units (CFU) per serving.
The Panel considers that the food/constituent, Bifidobacterium animalis subsp. lactis Bi-07, which is
the subject of the health claim, is sufficiently characterised.
3.2. Relevance of the claimed effect to human health
The claimed effect proposed by the applicant is ‘improvement of lactose digestion’. The proposed
target population is ‘persons with lactose maldigestion’.
Lactose maldigestion results from a reduced enzymatic capacity to digest lactose. Individuals with
lactose maldigestion may display symptoms after lactose consumption such as nausea, diarrhoea and
gastrointestinal (GI) discomfort (e.g. cramping, bloating and flatulence) (EFSA NDA Panel, 2016b).
The scientific substantiation of health claims on improved lactose digestion that were assessed
previously was based on human intervention studies showing an effect of the food/constituent on
symptoms of lactose maldigestion (subjective outcomes), as well as an increase in lactose digestion
(objectively measured by the breath hydrogen concentration method) when consumed with lactose-
containing foods by individuals with symptoms of lactose maldigestion, and also on the biological
plausibility of the effect. The characterisation of the study populations (i.e. individuals with symptoms
of lactose maldigestion, irrespective of the cause) in the studies submitted for the substantiation of
these claims is particularly important. Individuals with symptoms of lactose maldigestion could be
identified through the appearance of symptoms upon lactose consumption and which respond to
lactose withdrawal (EFSA NDA Panel, 2016b). Genetic testing may also be used as a first-stage
screening test for individuals with lactose maldigestion.
The Panel considers that increasing lactose digestion is a beneficial physiological effect for
individuals with lactose maldigestion provided that the symptoms of lactose maldigestion are improved.
3.3. Scientific substantiation of the claimed effect
The applicant performed a literature search on 24 September 2019 in the following databases:
Allied & Complementary MedicineTM, BIOSIS Previews®, CAB ABSTRACTS, Embase®, Foodline®:
SCIENCE, FSTA, MEDLINE® and NTIS (National Technical Information Service). Keywords used for Bi-
07 were ‘Bifidobacterium animalis’ or ‘Bifidobacterium lactis’ or ‘Bifidobacterium infantis’ or ‘B. infantis’
or ‘BBI’ or ‘B. lactis’ or ‘B. animalis’ or ‘Bi-07’, ‘Bi07’, ‘Bi 07’, ‘BI-07’, ‘BI07’, ‘BI 07’ and terms related to
outcome were ‘lactose’ or ‘lactase’.
No pertinent human intervention studies were retrieved by the search. The applicant submitted two
unpublished human intervention studies as pertinent to the health claim (Donazzolo, 2019 unpublished;
Uebelhack, 2019 unpublished).
They were both randomised, double-blind, cross-over, three-sequence, placebo-controlled, positive-
controlled studies which investigated a single-dose effect of Bi-07 on lactose digestion using the
hydrogen breath test (HBT), and on gastrointestinal (GI) symptoms. All participants included in the
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studies had lactose maldigestion as confirmed by genetic testing. The two studies were carried out
using a similar design.
Upon a request from EFSA, the applicant clarified that both studies were designed to study the
effect of Bi-07 on lactose digestion assessed by the HBT. The studies were not powered to assess the
effect of Bi-07 on GI symptoms. The applicant stated also that lactose maldigestion (i.e. the presence
of lactose in the colonic lumen) does not necessarily lead to lactose intolerance (‘symptomatic lactose
maldigestion’). Factors which determine whether undigested lactose causes lactose intolerance include
the amount of lactose ingested, small intestinal lactase activity, gastric emptying rate, transit time and
GI microbiota composition (Vesa et al., 2000; de Vrese et al., 2001; Montalto et al., 2005).
Individuals (aged 25–60 years, both sexes) with self-declared, suspected or medically diagnosed
lactose maldigestion were recruited into the studies by advertisements, by verbal communication of
the research centres staff, and with the use of the research centres databases. Lactose maldigestion
was confirmed at a screening visit by the ingestion of a lactose solution (25 g lactose in water or fat-
free milk) by participants and a subsequent increase in breath hydrogen with ≥ 20 ppm. This threshold
was in line with the conclusions of a North American consensus document (Rezaie et al., 2017).
Maximum mean (standard deviation (SD)) breath hydrogen concentrations of included participants at
the screening visits were 101  47.1 ppm in the study by Donazzolo (2019 unpublished) and
73.1  29.6 ppm in the study by Uebelhack (2019 unpublished). Lactose maldigestion was verified, in
addition, in all participants during the study by a gene test that screened for the most common single
nucleotide polymorphisms associated with lactose maldigestion (Enattah et al., 2002; Tishkoff et al.,
2007). Individuals with an increase of less than 20 ppm in breath hydrogen within 3 hours from
baseline were excluded from the study. People with GI diseases, with history of abdominal surgeries,
with recent antibiotic treatment, with history of alcohol abuse and regular smokers were excluded.
Randomisation was performed using an online tool incorporated into the electronic case report
forms (eCRF). Power calculation was based on a 35% decrease in the incremental area under the
curve (iAUC; ppm x h) of breath hydrogen concentrations for Bi-07 compared with placebo (the
expected effect was based on the results of a previously performed study by Sanders et al. (1992),
assuming an SD of 0.7 and a 10% attrition rate. In order to reach 90% power at a significance level of
5%, 34 participants were needed and recruited into both studies.
In each study, three acute lactose challenges (25 g) were performed. One sachet containing either
placebo (maltodextrin), 1.8 9 1012 CFU Bi-07, or 4500 Food Chemicals Codex (FCC) units of lactase
with maltodextrin as a carrier, was mixed using a blender by study personnel with 250 mL of water
and 25 g lactose (Donazzolo, 2019 unpublished), or with 521 mL of fat-free milk containing 25 g
lactose (Uebelhack, 2019 unpublished) immediately before administration. The mixture was consumed
by participants within prespecified time periods (i.e. in Donazzolo (2019 unpublished) within
30 seconds from preparation and in Uebelhack (2019 unpublished) within 5 minutes). The challenges
were carried out in random order using the Williams design for cross-over studies with 7-day wash-out
periods in between.
Breath gas (hydrogen, methane and carbon dioxide) measurements were performed immediately
after the ingestion of the study products (after 5 min from the start of the challenge) and every
30 minutes for 6 hours after the start of the challenge.
GI symptoms were assessed with the use of a non-validated questionnaire which was filled in
15 min before the start of the challenge, 5 min after the start of the challenge and every 60 minutes
from the start of the challenge until the end of the monitoring period. Abdominal pain, flatulence,
bloating and nausea were assessed by using a 4-point Likert scale (none, mild, moderate, severe),
vomiting, bowel movements and diarrhoea were rated as absent or present. If bowel movements and/
or diarrhoea were rated as present, the Bristol stool scale was used to assess stool consistency and a
number of bowel movements were recorded. The Panel notes that the assessment method of GI
symptoms was not validated. The Panel also notes that 4-point Likert scales are commonly used in the
assessment of GI symptoms and that symptoms were evaluated individually without combining them
into an overall GI symptom score that would have required validation.
The primary outcome measure of the study was the difference in breath hydrogen concentrations
between (1) the Bi-07 and the placebo periods, (2) the lactase and the placebo periods and (3) a non-
inferiority analysis between the Bi-07 and the lactase periods.
Secondary outcome measures included breath hydrogen peak values, cumulative breath hydrogen
values and the severity of abdominal pain, flatulence, bloating, nausea, vomiting, bowel movements
and diarrhoea.
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The multiple testing strategy for the primary outcome followed a fixed-sequence testing strategy in
the order indicated above.
In the statistical analysis, iAUC was analysed on the natural log-transformed scale. The linear mixed
model that was used included baseline breath hydrogen concentrations as a covariate and sequence,
period and treatment as fixed effects and participant within sequence as random effect. Results are
presented as ratios of geometric least squares means (LSM) and the associated 95% CIs. A two-sided
95% CI for the difference (Bi-07 – lactase) was applied in the evaluation of the non-inferiority
hypothesis. The non-inferiority margin was set at 1.25. Carry-over effects were evaluated separately
by adding a first-order carry-over effect into the model described above.
The presence of bowel movements and diarrhoea was analysed using a logistic regression model
with random intercepts. The period-wise maximum severity of abdominal pain, flatulence, bloating and
nausea was analysed using mixed effects cumulative logit-models for ordinal responses and logistic
regression for modelling the odds of higher ordered severities (i.e. at least moderate). Stool
consistency was evaluated descriptively.
The primary analysis was conducted on the per protocol (PP) population. The intention-to-treat
(ITT) population was used to support the primary evaluations.
In Donazzolo (2019), 34 participants were randomised (68% women, mean age
49.2  11.3 years). All of them finished the study. Two participants vomited during the Bi-07 challenge
and both were excluded from the PP population.
There was a statistically significant sequence effect in the study. According to the authors of the
study report, this was mainly due to two sequences (Bi-07-lactase-placebo and placebo-lactase-Bi-07)
which showed lower mean breath hydrogen concentrations than the other sequences.
In the PP population, there was a statistically significant decrease in the iAUC for breath hydrogen
in the Bi-07 compared with the placebo period (mean values of iAUC  SD: 134.7  120.76 vs.
235.7  142.80 ppm/hour; geometric LSM ratio 0.227 (95%CI 0.095; 0.543); p = 0.0012). There was
no statistically significant difference between lactase and placebo (162.6  111.92 vs.
235.7  142.80 ppm/hour; 0.493 (0.210; 1.156); p = 0.1022). The non-inferiority of Bi-07 vs. lactase
was shown as the upper limit of the geometric LMS ratio 95% CI (1.096) and was below the non-
inferiority margin of 1.25. The Panel notes that the results of the non-inferiority analysis cannot be
interpreted in the absence of significant differences between lactase and placebo. The results of the
ITT analysis were in line with those of the PP population.
There were no statistically significant differences between Bi-07 and placebo or Bi-07 and lactase in
the odds of developing at least moderate abdominal pain, flatulence and bloating. The odds of higher
severity classes of nausea were significantly increased in the Bi-07 period compared with placebo (OR
4.31 (95%CI 1.57; 11.85) or with lactase (6.98 (2.42; 20.1). The Panel notes the large uncertainty
around the effect and that the results were not corrected for multiple testing of outcomes. The
Panel also notes that the study was not designed to investigate GI symptoms.
The Panel considers that this study shows an effect of a single dose of Bi-07 (1012 CFU) suspended
in water with 25 g lactose on lactose digestion assessed by HBT in individuals with lactose
maldigestion. However, the increased lactose digestion was not associated with a reduction of GI
symptoms of lactose maldigestion in the same individuals.
In Uebelhack (2019 unpublished), 34 participants were randomised (56% women, mean age
37.7  11.1 years), and all of them completed the study. One individual was ex post excluded from PP
analysis because of the regular use of tobacco (that was an exclusion criterion).
Results from this study also showed a significant sequence effect for one of the sequences
(placebo-Bi-07-lactase), which was different from the sequences for which a significant sequence
effect was found in the study by Donazzolo (2019 unpublished). According to the author of the study
report, this was due to two outliers whose breath hydrogen iAUCs were zero after lactase
administration. Removing these two participants in a sensitivity analysis led to the results of the
analysis of the sequence effect to become non-statistically significant.
In addition, a carry-over effect was observed. The author of the study report explained that in six
participants, Bi-07 was detected in faeces in the placebo period that was preceded by the Bi-07
administration. In this period, they also had breath hydrogen iAUCs that were exceptionally low. These
low iAUCs could, according to the author, be explained by the carry-over effect that was observed.
In the PP population, iAUC for breath hydrogen was statistically significant lower in the Bi-07 period
compared with placebo (mean values  SD: 172.5  86.33 vs. 219.4  101.21 ppm/hour; geometric
LSM ratio 0.462 (95% CI 0.249; 0.859); p = 0.0156). Significant differences (i.e. lower iAUC) were also
found for lactase vs. placebo (mean values  SD: 123.0  121.20 vs. 219.4  101.21; geometric LSM
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ratio 0.190 (0.102; 0.365); p < 0.0001). The non-inferiority of Bi-07 vs. lactase was not shown as the
upper limit of the geometric LSM ratio’s 95% CI (4.55) was above the non-inferiority margin of 1.25.
The results of the ITT analyses were in line with those of the PP population.
There were no statistically significant differences between Bi-07 and placebo or Bi-07 and lactase in
the odds of higher severity classes (i.e. at least moderate) bloating and nausea. The odds of higher
severity classes of abdominal pain and flatulence were significantly increased in the Bi-07 period
compared with lactase (OR 3.13 (95%CI 1.10; 8.87) and 3.4 (1.29; 9.00), respectively, but not
compared with placebo (1.02 (0.38; 2.74) and 0.86 (0.34; 2.19), respectively. The Panel notes the
large uncertainty around the effect and that the results were not corrected for multiple testing of
outcomes. The Panel also notes that the study was not designed to investigate GI symptoms.
The Panel considers that this study shows an effect of a single dose of Bi-07 (1012 CFU) suspended
in fat-free milk containing 25 g lactose on lactose digestion assessed by HBT in individuals with lactose
maldigestion. However, the increased lactose digestion was not associated with a reduction of GI
symptoms of lactose maldigestion in the same individuals.
Proposed mechanism of action
The applicant claims that Bi-07 exhibits lactase activity. The lactase activity of Bi-07 was determined
in three in vitro studies: by assessing lactase activity of Bi-07 itself (Rasinkangas, 2019 unpublished;
Forssten, 2019 unpublished) and indirectly by assessing residual lactose content (Forssten and
Marttinen, 2019; unpublished).
The study conducted by Rasinkangas (2019 unpublished) was carried out as part of a quality
control and stability analysis of the products used in each of the clinical studies described above
(Donazzolo, 2019 unpublished; Uebelhack, 2019 unpublished). In this study, the lactase activity of Bi-
07 was 23.0 FCC/g and 23.6 FCC/g in the refrigerated reference samples of the batches used in
Uebelhack (2019 unpublished) and Donazzolo (2019 unpublished), respectively. Analyses of
refrigerated returned samples from the study sites yielded a lactase activity of 28.6 FCC/g and
32.2 FCC/g, respectively. In comparison, the activity of lactase administered in the studies ranged from
777 to 871 FCC/g. The low levels of lactase activity measured in the Bi-07 samples were explained by
the author to be due to the location of the lactase enzyme within the viable cells of the bacteria. The
increase in measured FCC/g for Bi-07 is thought to be due to a reduction in the viability over time,
which may result in the release of the enzyme from the cells. The increase in the activity of the lactase
samples was explained by measurement uncertainty.
Forssten (2019) assessed the lactase activity of different bacterial strains, among them Bi-07, either
when lactose was added to sealed tubes containing the cultures of the strain (experiment 1) or in
simulated human upper GI tract conditions (experiment 2). The lactase activity was measured by
comparing to standards of a p-nitrophenyl-b-d-galactopyranoside standard curve. The activity of Bi-07
was similar to several yoghurt cultures (around 1.1 nmol/g/min) in the first experiment, including
Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus, which have been evaluated
with a favourable outcome for their effect on lactose digestion by the Panel (EFSA NDA Panel, 2010).
In experiment 2, Bi-07 showed, using descriptive statistics only, a higher lactase activity than the
above-mentioned yoghurt cultures both in the stomach and the duodenal simulations and higher
activity compared with the purified lactase in the duodenal stage.
Forssten and Marttinen (2019) assessed the lactase activity of Bi-07 in fat-free milk, as measured
by the residual lactose content. Fat-free milk (500 mL) at 37°C was exposed to a dose of 6 g of
freeze-dried Bi-07 (1.8 x 1012 CFU), placebo (6 g maltodextrin) or 4,500 FCC of lactase (two different
samples: food grade and laboratory grade). Samples were collected during 6 h of incubation with 30-
min intervals during the first hour and thereafter with 1-h intervals. In order to stop the enzymatic
activity, the samples were placed for 10 min in a water bath at 98°C. The lactose content of samples
was determined using a UV-method. Bi-07 caused a decrease of the lactose amount that was similar
to the two lactase samples, while for the untreated milk and the placebo samples, there was no
change in the amount of lactose during the 6-hour measurements. The difference between Bi-07 and
placebo was statistically significant in RM-ANOVA analysis.
The Panel considers that the evidence provided in the in vitro studies, either assessed directly by
measuring the enzymatic activity, or indirectly by assessing residual lactose content, shows that Bi-07
exhibits lactase activity.
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Weighing the evidence
In weighing the evidence, the Panel considered that the two human intervention studies provided
show that consumption of Bi-07 (1012 CFU) increases lactose digestion in individuals with lactose
maldigestion and that Bi-07 exhibits lactase activity in vitro. However, the Panel also considered that
these studies provide no evidence that increasing lactose digestion through the consumption of Bi-07
(1012 CFU) improves GI symptoms of lactose maldigestion, which is considered a beneficial
physiological effect.
The Panel concludes that a cause and effect relationship has not been established between the
consumption of Bifidobacterium animalis subsp. lactis Bi-07 and a beneficial physiological effect (i.e.
the improvement of symptoms of lactose maldigestion) in individuals with lactose maldigestion.
4. Conclusions
On the basis of the data presented, the Panel concludes that:
• The food/constituent, Bifidobacterium animalis subsp. lactis Bi-07, which is the subject of the
health claim, is sufficiently characterised.
• The claimed effect proposed by the applicant is ‘improvement of lactose digestion’. The target
population proposed by the applicant is ‘persons with lactose maldigestion’. Increasing lactose
digestion is a beneficial physiological effect for individuals with lactose maldigestion provided
that the symptoms of lactose maldigestion are improved.
• A cause and effect relationship has not been established between the consumption of
Bifidobacterium animalis subsp. lactis Bi-07 and a beneficial physiological effect (i.e. the
improvement of symptoms of lactose maldigestion) in individuals with lactose maldigestion.
Documentation as provided to EFSA
Health claim application on Bifidobacterium animalis subsp. lactis Bi-07 contributes to the
improvement of lactose digestion in individuals with lactose maldigestion pursuant to Article 13(5) of
Regulation (EC) No 1924/2006 (Claim serial No: 0492_IE). Submitted by DuPont Nutrition Biosciences
ApS Langebrogade 1 DK-1411, Copenhagen K, Denmark.
Steps taken by EFSA
1) This application was received by EFSA on 8/01/2020.
2) The scope of the application was proposed to fall under a health claim based on newly
developed scientific evidence.
3) The scientific evaluation procedure started on 26/02/2020.
4) On 27/02/2020, the Working Group on Claims of the NDA Panel agreed on a list of questions
for the applicant to provide additional information to accompany the application. The
scientific evaluation was suspended on 12/03/2020 and was restarted on 26/03/2020, in
compliance with Article 18(3) of Regulation (EC) No 1924/2006.
5) During its meeting on 01/07/2020, the NDA Panel, having evaluated the data, adopted an
opinion on the scientific substantiation of a health claim related to the consumption of
Bifidobacterium animalis subsp. lactis Bi-07 and improved digestion of lactose in individuals
with lactose maldigestion.
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ATCC American Type Culture Collection
CFU Colony Forming Unit
CI Confidence Interval
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DGCC Danisco Global Culture Collection
FCC Food Chemicals Codex
GI gastrointestinal
GRAS Generally Recognised As Safe
HBT hydrogen breath test
iAUC incremental Area Under the Curve
ITT Intention To Treat
LSM least squares means
NCBI National Center for Biotechnology Information
NDA Panel Panel on Nutrition, Novel Foods and Food Allergens
NIH National Institute of Health
NTIS National Technical Information Service
PP Per Protocol
RM ANOVA Repeated Measures-Analysis of Variance
SD Standard Deviation
UV Ultraviolet
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